Loading
A phase 1/2 trial of SHR-A2102, Adebrelimab, SHR-8068 in non-small-cell lung cancer and small-cell lung cancer, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.
A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT06589778 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 124 participants planned, started 2024-09-27 and due to reach its primary completion in 2026-04-30. Interventions recorded: SHR-A2102, Adebelimab (SHR-1316), SHR-8068. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies.
Shares SHR-A2102, SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/